Creative Planning’s TriSalus Life Sciences TLSI Stock Holding History

Creative Planning’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,216	Closed	-$137K	–	3004
2023 Q4	$137K	Buy	+16,216	New	+$83.5K	﹤0.01%	2524
2022 Q1	–	Sell	-25,000	Closed	-$247K	–	2440
2021 Q4	$247K	Hold	25,000	–	–	﹤0.01%	1752
2021 Q3	$248K	Buy	+25,000	New	+$245K	﹤0.01%	1716

Other funds holding TLSI

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CWM

Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LNWWM

Laird Norton Wetherby Wealth Management San Francisco, California $2.45B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Anson Capital Tyrone, Georgia $146M AUM 18.69% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Creative Planning's TLSI Position: Q1 2024 in Review

Creative Planning sold out of TriSalus Life Sciences (TLSI) in Q1 2024, closing a stake of 16,216 shares — an estimated $137K sold.

Creative Planning first reported a position in TLSI in Q3 2021 and held it in 3 quarters. The position peaked at $248K in Q3 2021. 26 funds tracked by Wall St. Rank hold TLSI as of Q1 2024.

Creative Planning reported no remaining TriSalus Life Sciences position as of Q1 2024 after selling out during the quarter.
Creative Planning sold 16,216 TriSalus Life Sciences shares in Q1 2024, an estimated $137K.
Creative Planning first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 3 quarters.
Creative Planning's TriSalus Life Sciences position peaked at $248K in Q3 2021.
26 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2024.

Based on Creative Planning's 13F filing for Q1 2024, filed 13 May 2024.